BiomeBank Announces Regulatory Approval for Donor Derived Microbiome Drug

Hast du eine Frage? Fordern Sie einen Rückruf an

BiomeBank Announces Regulatory Approval for Donor Derived Microbiome Drug

Whitley Workstation customer, BiomeBank, receives TGA (Therapeutic Goods Administration) approval for a donor derived microbiome drug. The drug - BIOMICTRA - will be used for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection. A recent article in the publication Microbiome Times tell the story:

https://www.microbiometimes.com/biomebank-announces-regulatory-approval-for-donor-derived-microbiome-drug/

BiomeBank, based in Adelaide, Australia, are the proud owners of a Whitley A85 HEPA Workstation, which will be joined by an A55 Workstation early in 2023.

Chat

Wähle ein Land

Please select your country below. If it does not appear in the list, please select ‘England’ and you will be able to find your local distributor in the ‘Overseas Distributors’ section.

Teile das

Bitte wählen Sie Ihre bevorzugte Sprache aus der Liste unten aus

Anmeldung

Sie haben noch kein Konto? Klicken Sie hier

Haben Sie Ihr Passwort vergessen? Klicken Sie hier